key: cord-0826719-324jgy1r
authors: Vakirlis, Authors: E; Bakirtzi, K; Papadimitriou, I; Vrani, F; Sideris, N; Lallas, A; Ioannides, D; Sotiriou, E
title: ‘’Treatment adherence in psoriatic patients during COVID‐19 pandemic: Real‐world data from a tertiary hospital in Greece’’
date: 2020-06-18
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.16759
sha: f4b843c81a4eb46ac4d36b7d0b3d00d65ed30865
doc_id: 826719
cord_uid: 324jgy1r

COVID‐19 pandemic raised questions both in dermatologists and in patients about the use of immunosuppressive medications. Although dermatologic societies recommend the continuing of psoriatic systemic therapies and biologics, little is known about treatment adherence in psoriatic patients during COVID‐19 outbreak. Medication self‐management may feel burdensome to patients with psoriasis due to the nature of treatments and many of them face additional challenges as they may suffer from comorbidities. Under these already difficult conditions, COVID‐19 disease puts extra pressure on individuals and may undermine adherence. Acknowledging treatment non‐adherence as a consequence of conflicting goals may help to find the reasons for but, most important, solutions to non‐adherence especially during public health crises. The objective of our study was to evaluate the adherence of psoriatic patients in traditional systemic treatment as well as biologics and identify possible influencing factors of drug interruption during COVID‐10 pandemic.

This article is protected by copyright. All rights reserved apremilast, adalimumab, etanercept, brodalumab, ustekinumab, secukinumab) and reasons for non-adherence. Their answers were checked against electronic pharmacy refill and prescription records. Influencing factors regarding drug discontinuation such as age and comorbid conditions were also analyzed.

Our study showed that most patients (76.4% vs. 23.6%) continued to take their medicines, as prescribed. However, patients with more than three comorbidities were over 6 times more likely not to adhere to their treatment (p=0.03; O.R. 6.29, 1.23-2.27 95% C.I.). Age, type of treatment or any particular type of comorbidity did not appear to influence the therapeutic routine of psoriatic patients during the COVID-19 outbreak.

Despite the satisfactory safety profile of biologics and psoriatic systemic treatment, there is concern that such therapies could reduce resistance to infection. This concern is inevitably heightened during COVID-19 outbreak. Restrictive measures were essential, and the approach to psoriatic patients had to be adjusted; telecounselling was mandatory to offer patients support and not to deprive them of dermatologic care. In Greece, patients were able to receive their electronic prescriptions by e-mail or text messages. The high rates of adherence in our study could, therefore, be partially attributed to the seamless access patients had to their medical treatment.

The majority of our patients continued to receive their therapies as prescribed irrespective of the type of medication. In the international literature, adherence to biologics may reach 100% according to self-reports among psoriatic patients, while adherence to systemic agents ranges between 46 to 96% 2-5 . Moreover, contrary to popular perception that some demographic features are related to non-adherence, our findings are in line with several systematic reviews, where there is no consistent correlation between demographic traits, particularly age, and adherence in psoriatic

Drug discontinuation in our patients seemed to be driven exclusively by concerns about the potential for coronavirus infection. The most important risk factors that worsen the prognosis of COVID-19 disease are comorbidities that are also present in psoriatic patients 1, 7 . Our results are agreed with relevant reports which suggest that

This article is protected by copyright. All rights reserved the presence of comorbidities are linked to sustained drug survival. Several authors support the rationale that the more patients are accustomed to medication use for coexisting health issues, the higher and more long-lasting their adherence to additional treatments 8 . Our study suggests that necessity beliefs about therapy are a prerequisite for taking medicines and that the need for treatment appears to outweigh the fears about the medication.

Conclusively, we recommend embracing a nonjudgmental approach that acknowledges difficulties in adherence, especially in situations of increased public health risks, and encouraging patients to discuss factors contributing to non-adherence. This approach may assist patients to determine conflicting goals and find possible solutions, support psychological welfare and improve adherence. 

Managing Cutaneous Immune-Mediated Diseases During the COVID-19

Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature

Drug survival rates and reasons for drug discontinuation in psoriasis

Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression

Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic

A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases

COVID-19 and psoriasis : should we fear for patients treated with biologics? Dermatol Ther

Characterization of adherence and persistence profile in a real-life population of patients treated with adalimumab

Accepted Article